ArticleFrontiers in neuroscience2026
Diagnostic redirection in dementia-first spinocerebellar ataxia type 17: a family-based case report and focused literature review.
Article in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Spinocerebellar ataxia type 17 (SCA17) is an autosomal dominant repeat-expansion disorder with marked phenotypic heterogeneity. Cognitive and neuropsychiatric symptoms may dominate early recognition and initially suggest a primary dementia syndrome. We aimed to illustrate diagnostic redirection in dementia-first SCA17 through integrated clinical, imaging, familial, and molecular assessment. Case presentation: We describe the clinical course, neurological findings, cognitive and functional assessments, ancillary investigations, neuroimaging, pedigree information, and molecular genetic findings of a proband with SCA17 and one tested at-risk adult relative. To contextualize the family, we conducted a focused literature review of genetically confirmed SCA17 case and family reports identified through PubMed, Web of Science, Embase, China National Knowledge Infrastructure (CNKI), and Wanfang up to April 16, 2026. Findings: Repeat-expansion testing established SCA17 in a proband who had initially presented through a dementia-first clinical pathway, with TATA-box binding protein (TBP) alleles of 37/51 repeats. Targeted presymptomatic cascade testing identified the same expanded 51-repeat allele in her asymptomatic adult daughter. Review of 25 published studies showed broad variation in age at onset, TBP repeat size, family context, presenting syndrome, and cumulative phenotype, including cognition-dominant, behavior-dominant, Huntington disease-like, parkinsonian, dystonic, choreic, seizure-associated, and atypical neuroimaging presentations. Conclusion: The present family illustrates a dementia-first route to SCA17 recognition, in which the initial syndrome-based dementia interpretation remained etiologically provisional as cerebellar signs, cerebellar-predominant atrophy, autosomal-dominant family context, and TBP expansion were integrated. This case-based perspective is intended to support etiological reconsideration in selected dementia-first presentations, rather than to serve as validated clinical criteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.